In 2019, the Food and Drug Administration (FDA) approved brexanolone, marketed by Sage Therapeutics as Zulresso, as a treatment for postpartum depression (PPD). As a neurosteroid, brexanolone represents a novel approach to the treatment of postpartum mood disorders. One of the most exciting things about brexanolone is the rapidity of the response, with the initial… Read More »
Essential Reads: ADHD in Girls and Women In childhood, ADHD is clearly more common in boys than in girls; however, in adult samples, the sex differences in prevalence are mush smaller. There is also increasing recognition that girls and women may present with a different constellation of symptoms and behaviors. For example, in children, girls… Read More »
In a given year, about 10% of mothers in the United States experience a major depressive episode (MDE). Roughly translated, this means about 1 in 10 children is exposed to maternal depression each year (Ertel et al, 2011). While much attention has focused on postpartum depression, which affects about 10% to 15% of women, mothers… Read More »
Munich – With the new release of its early warning system Risk Guard RSU is becoming one of the first financial service providers in Germany to use machine learning in an operational risk management system. Complementing existing models, new algorithms enable the system to analyse reports from nearly 300 newspapers and journals for information about… Read More »